Development of high-growth influenza H7N9 prepandemic candidate vaccine viruses in suspension MDCK cells.
Candidate vaccine virus
Chemically defined medium
H7N9
Highly pathogenic avian influenza
Reverse genetics
Suspension MDCK cells
Journal
Journal of biomedical science
ISSN: 1423-0127
Titre abrégé: J Biomed Sci
Pays: England
ID NLM: 9421567
Informations de publication
Date de publication:
02 Apr 2020
02 Apr 2020
Historique:
received:
16
09
2019
accepted:
27
03
2020
entrez:
4
4
2020
pubmed:
4
4
2020
medline:
12
9
2020
Statut:
epublish
Résumé
Influenza vaccine manufacturers traditionally use egg-derived candidate vaccine viruses (CVVs) to produce high-yield influenza viruses for seasonal or pandemic vaccines; however, these egg-derived CVVs need an adaptation process for the virus to grow in mammalian cells. The low yields of cell-based manufacturing systems using egg-derived CVVs remain an unsolved issue. This study aimed to develop high-growth cell-derived CVVs for MDCK cell-based vaccine manufacturing platforms. Four H7N9 CVVs were generated in characterized Vero and adherent MDCK (aMDCK) cells. Furthermore, reassortant viruses were amplified in adherent MDCK (aMDCK) cells with certification, and their growth characteristics were detected in aMDCK cells and new suspension MDCK (sMDCK) cells. Finally, the plaque-forming ability, biosafety, and immunogenicity of H7N9 reassortant viruses were evaluated. The HA titers of these CVVs produced in proprietary suspension MDCK (sMDCK) cells and chicken embryos were 2- to 8-fold higher than those in aMDCK cells. All H7N9 CVVs showed attenuated characteristics by trypsin-dependent plaque assay and chicken embryo lethality test. The alum-adjuvanted NHRI-RG5 (derived from the fifth wave H7N9 virus A/Guangdong/SP440/2017) vaccine had the highest immunogenicity and cross-reactivity among the four H7N9 CVVs. Finally, we found that AddaVax adjuvant improved the cross-reactivity of low pathogenic H7N9 virus against highly pathogenic H7N9 viruses. Our study indicates that cell-derived H7N9 CVVs possessed high growth rate in new sMDCK cells and low pathogenicity in chicken embryo, and that CVVs generated by this platform are also suitable for both cell- and egg-based prepandemic vaccine production.
Sections du résumé
BACKGROUND
BACKGROUND
Influenza vaccine manufacturers traditionally use egg-derived candidate vaccine viruses (CVVs) to produce high-yield influenza viruses for seasonal or pandemic vaccines; however, these egg-derived CVVs need an adaptation process for the virus to grow in mammalian cells. The low yields of cell-based manufacturing systems using egg-derived CVVs remain an unsolved issue. This study aimed to develop high-growth cell-derived CVVs for MDCK cell-based vaccine manufacturing platforms.
METHODS
METHODS
Four H7N9 CVVs were generated in characterized Vero and adherent MDCK (aMDCK) cells. Furthermore, reassortant viruses were amplified in adherent MDCK (aMDCK) cells with certification, and their growth characteristics were detected in aMDCK cells and new suspension MDCK (sMDCK) cells. Finally, the plaque-forming ability, biosafety, and immunogenicity of H7N9 reassortant viruses were evaluated.
RESULTS
RESULTS
The HA titers of these CVVs produced in proprietary suspension MDCK (sMDCK) cells and chicken embryos were 2- to 8-fold higher than those in aMDCK cells. All H7N9 CVVs showed attenuated characteristics by trypsin-dependent plaque assay and chicken embryo lethality test. The alum-adjuvanted NHRI-RG5 (derived from the fifth wave H7N9 virus A/Guangdong/SP440/2017) vaccine had the highest immunogenicity and cross-reactivity among the four H7N9 CVVs. Finally, we found that AddaVax adjuvant improved the cross-reactivity of low pathogenic H7N9 virus against highly pathogenic H7N9 viruses.
CONCLUSIONS
CONCLUSIONS
Our study indicates that cell-derived H7N9 CVVs possessed high growth rate in new sMDCK cells and low pathogenicity in chicken embryo, and that CVVs generated by this platform are also suitable for both cell- and egg-based prepandemic vaccine production.
Identifiants
pubmed: 32241276
doi: 10.1186/s12929-020-00645-y
pii: 10.1186/s12929-020-00645-y
pmc: PMC7115086
doi:
Substances chimiques
Influenza Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Subventions
Organisme : Ministry of Science and Technology, Taiwan
ID : MOST 106-3114-Y404-002; 107-0324-01-19-13
Références
PLoS One. 2011 Jan 24;6(1):e14578
pubmed: 21283675
PLoS One. 2015 Mar 23;10(3):e0120793
pubmed: 25799397
Sci Transl Med. 2013 May 15;5(185):185ra68
pubmed: 23677594
Vaccine. 2015 Jan 3;33(2):374-81
pubmed: 25448099
J Virol. 2014 Jun;88(12):7016-23
pubmed: 24719414
Virol J. 2019 Jul 2;16(1):87
pubmed: 31266524
J Virol. 2008 Nov;82(21):10502-9
pubmed: 18768983
Euro Surveill. 2017 May 11;22(19):
pubmed: 28537546
Vaccine. 2019 Oct 8;37(43):6526-6534
pubmed: 31500967
Vaccine. 2016 Jan 12;34(3):328-33
pubmed: 26657023
Proc Natl Acad Sci U S A. 2000 May 23;97(11):6108-13
pubmed: 10801978
Clin Diagn Lab Immunol. 1998 Jan;5(1):114-7
pubmed: 9455891
Trends Microbiol. 2012 Mar;20(3):103-5
pubmed: 22257962
J Microbiol Biotechnol. 2018 Jun 28;28(6):997-1006
pubmed: 29642288
Hum Vaccin Immunother. 2015;11(5):1223-34
pubmed: 25875691
Emerg Infect Dis. 2018 Oct;24(10):1910-1913
pubmed: 30226171
Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14802-7
pubmed: 19706449
Vaccine. 2014 Jul 31;32(35):4485-94
pubmed: 24962757
Vaccine. 2010 Aug 31;28(38):6256-64
pubmed: 20638458
PLoS One. 2015 Nov 05;10(11):e0141686
pubmed: 26540170
Vaccine. 2018 May 24;36(22):3146-3152
pubmed: 28342667
PLoS One. 2011;6(10):e24057
pubmed: 22022351
Vaccines (Basel). 2018 Mar 30;6(2):
pubmed: 29601497
Influenza Other Respir Viruses. 2009 Nov;3(6):287-95
pubmed: 19903211
J Virol. 2019 Sep 12;93(19):
pubmed: 31270231
J Formos Med Assoc. 2017 Mar;116(3):210-212
pubmed: 28259506
Nat Commun. 2015 Sep 02;6:8148
pubmed: 26334134
Arch Virol. 2001 Dec;146(12):2275-89
pubmed: 11811679
Sci Transl Med. 2011 Jun 1;3(85):85ra48
pubmed: 21632986
Emerg Microbes Infect. 2013 May;2(5):e27
pubmed: 26038464
Lancet. 2013 Jun 29;381(9885):2273-9
pubmed: 23726392